Novo Nordisk wins FDA approval for weekly Sogroya in children with Turner syndrome

Key highlights
  • FDA approval covers children aged 2.5 years and older with growth failure associated with Turner syndrome.
  • REAL8 randomized 105 patients to weekly Sogroya® at 0.24 mg/kg or daily somatropin at 0.05 mg/kg.
  • At week 52, annualized height velocity was 8.9 cm/year with Sogroya® and 9.7 cm/year with somatropin.
  • Reported adverse reactions in at least 10% of Sogroya®-treated patients included respiratory tract infection, nasopharyngitis and injection-site reaction.

FDA approval

The FDA approved once-weekly Sogroya® (somapacitan-beco) for children aged 2.5 years and older with growth failure associated with Turner syndrome. The long-acting growth hormone is also approved in the US for children with growth hormone deficiency, idiopathic short stature, short stature after being born small for gestational age, and growth failure associated with Noonan syndrome, as well as adults with growth hormone deficiency.

REAL8 results

The approval was based on the phase 3 REAL8 trial, which randomized 105 children aged 2.5 to 10 years with Turner syndrome to weekly Sogroya® (68 patients) or daily somatropin (37 patients). At week 52, mean annualized height velocity was 8.9 cm/year with Sogroya® and 9.7 cm/year with somatropin. Mean change in annualized height standard deviation score was 0.77 and 0.86, respectively. Participants are continuing in a two-year safety extension phase.

Safety

Adverse reactions reported in at least 10% of Sogroya®-treated patients at week 52 included respiratory tract infection, nasopharyngitis, ear infection, fever, diarrhea, vomiting and injection-site reaction.

Source: Novo Nordisk

chemXplore Weekly

The week’s project milestones and project news from the chemical industry, free every Wednesday.

Free. One email a week. Unsubscribe any time. See our Privacy Policy.

Related articles

18 September 2026
Novo Nordisk’s Sogroya recommended by EMA CHMP for idiopathic short stature in children

Once-weekly somapacitan (Sogroya) receives CHMP positive opinion for children with idiopathic short stature; European Commission decision expected later this year.